文献速递冠心病

STEMI患者入院高敏肌钙蛋白T的预后价值

Prognostic value of admission high-sensitivity troponin in patients with ST-elevation myocardial infarction.
PubMed 文献 · Heart · 2021-09-20

该回顾性纵向观察研究纳入3113例接受直接经皮冠状动脉介入治疗的ST段抬高型心肌梗死患者,测量入院时和术后12小时高敏肌钙蛋白T。中位随访53个月,入院高敏肌钙蛋白T>515 ng/L独立预测住院死亡和总死亡,而12小时值无独立关联。

要点

  • 入院高敏肌钙蛋白T>515 ng/L独立预测STEMI患者住院死亡和总死亡。
  • 术后12小时高敏肌钙蛋白T与死亡率无独立关联。
  • 入院高敏肌钙蛋白T可改善风险分层,支持其预后价值。

核心结论

  • 入院时而非再灌注后12小时的高敏肌钙蛋白T可预测接受直接PCI的STEMI患者死亡率并改善风险分层。

研究设计与样本

  • 回顾性纵向观察研究,纳入英格兰东北部一所大学医院连续接受直接PCI的STEMI患者3113例,中位随访53个月。

主要发现

  • 入院高敏肌钙蛋白T>515 ng/L(第四四分位)经多变量调整后独立关联住院死亡(HR=2.53,95%CI 1.32-4.85,p=0.005)。
  • 入院高敏肌钙蛋白T>515 ng/L独立预测总死亡(HR=1.27,95%CI 1.02-1.59,p=0.029)。
  • 入院高敏肌钙蛋白T改善住院死亡风险重分类(NRI=0.588,p<0.001)和总死亡风险重分类(NRI=0.178,p=0.001)。
  • 12小时高敏肌钙蛋白T与死亡率无独立关联。

临床怎么用

  • 可考虑使用入院高敏肌钙蛋白T(>515 ng/L)辅助STEMI患者风险分层。
  • 常规12小时高敏肌钙蛋白T检测的成本效益受到质疑。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIM: Although the diagnostic usefulness of high-sensitivity cardiac troponin T (hs-cTnT) is well established in ST-segment elevation myocardial infarction (STEMI), its prognostic relevance in risk stratification of patients with STEMI remains obscure. This study sought to determine the prognostic value of pre-reperfusion (admission) and post-reperfusion (12-hour) hs-cTnT in patients with STEMI treated with primary percutaneous coronary intervention (PPCI). METHODS: Retrospective observational longitudinal study including consecutive patients with STEMI treated with PPCI at a university hospital in the northeast of England. hs-cTnT was measured at admission to the catheterisation laboratory and 12 hours after PPCI. Clinical, procedural and laboratory data were prospectively collected during patient hospitalisation (June 2010-December 2014). Mortality data were obtained from the UK Office of National Statistics. The study endpoints were in-hospital and overall mortality. RESULTS: A total of 3113 patients were included. Median follow-up was 53 months. Admission hs-cTnT >515 ng/L (fourth quartile) was independently associated with in-hospital mortality (HR=2.53 per highest to lower quartiles; 95% CI: 1.32 to 4.85; p=0.005) after multivariable adjustment for a clinical model of mortality prediction. Likewise, admission hs-cTnT >515 ng/L independently predicted overall mortality (HR=1.27 per highest to lower quartiles; 95% CI: 1.02 to 1.59; p=0.029). Admission hs-cTnT correctly reclassified risk for in-hospital death (net reclassification index (NRI)=0.588, p<0.001) and overall mortality (NRI=0.178, p=0.001). Conversely, 12-hour hs-cTnT was not independently associated with mortality. CONCLUSION: Admission, but not 12-hour post-reperfusion, hs-cTnT predicts mortality and improves risk stratification in the PPCI era. These results support a prognostic role for admission hs-cTnT while challenge the cost-effectiveness of routine 12-hour hs-cTnT measurements in patients with STEMI.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Coelho-Lima J, Georgiopoulos G, Ahmed J, et al. Prognostic value of admission high-sensitivity troponin in patients with ST-elevation myocardial infarction. Heart. 2021. PMID: 34544804. doi:10.1136/heartjnl-2021-319225

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。